JP2021500336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500336A5 JP2021500336A5 JP2020521860A JP2020521860A JP2021500336A5 JP 2021500336 A5 JP2021500336 A5 JP 2021500336A5 JP 2020521860 A JP2020521860 A JP 2020521860A JP 2020521860 A JP2020521860 A JP 2020521860A JP 2021500336 A5 JP2021500336 A5 JP 2021500336A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- dose
- subject
- combination according
- hu5f9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022186496A JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2024003136A JP2024024121A (ja) | 2017-10-18 | 2024-01-12 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574073P | 2017-10-18 | 2017-10-18 | |
| US62/574,073 | 2017-10-18 | ||
| PCT/US2018/056442 WO2019079549A1 (en) | 2017-10-18 | 2018-10-18 | TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022186496A Division JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500336A JP2021500336A (ja) | 2021-01-07 |
| JP2021500336A5 true JP2021500336A5 (https=) | 2021-10-07 |
| JP7308190B2 JP7308190B2 (ja) | 2023-07-13 |
Family
ID=64402251
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521860A Active JP7308190B2 (ja) | 2017-10-18 | 2018-10-18 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2022186496A Active JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2024003136A Withdrawn JP2024024121A (ja) | 2017-10-18 | 2024-01-12 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022186496A Active JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2024003136A Withdrawn JP2024024121A (ja) | 2017-10-18 | 2024-01-12 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210047416A1 (https=) |
| EP (2) | EP3697819B1 (https=) |
| JP (3) | JP7308190B2 (https=) |
| KR (1) | KR20200070341A (https=) |
| CN (1) | CN111315783A (https=) |
| AU (1) | AU2018351007B2 (https=) |
| CA (1) | CA3078430A1 (https=) |
| ES (1) | ES2938652T3 (https=) |
| PL (1) | PL3697819T3 (https=) |
| PT (1) | PT3697819T (https=) |
| SI (1) | SI3697819T1 (https=) |
| WO (1) | WO2019079549A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3402820T (pt) | 2016-01-11 | 2020-08-20 | Forty Seven Inc | Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados |
| JP7308191B2 (ja) | 2017-10-18 | 2023-07-13 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７剤ベースの卵巣癌療法 |
| CN111699005A (zh) | 2018-02-12 | 2020-09-22 | 四十七公司 | 使用抗cd47抗体和抗cd20抗体的抗癌方案 |
| EP3969484A4 (en) * | 2019-05-17 | 2023-07-05 | Nanjing GenScript Biotech Co., Ltd. | ANTI-CD47/ANTI-PD-L1 MULTIPLE ANTIGEN BINDING PROTEINS AND METHODS OF USE |
| CA3164623A1 (en) | 2019-12-17 | 2021-06-24 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
| CN113018429A (zh) * | 2019-12-24 | 2021-06-25 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗卵巢癌的药物组合 |
| US20230090014A1 (en) * | 2020-02-28 | 2023-03-23 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-cd47/anti-pd-l1 antibody and applications thereof |
| KR20230129482A (ko) * | 2021-01-08 | 2023-09-08 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 항pd-l1/항cd47 천연항체 구조 형태의 헤테로다이머이중특이성 항체 및 그 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160095939A1 (en) * | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2017019767A1 (en) * | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| RU2748401C2 (ru) * | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
| JP2018538321A (ja) * | 2015-12-28 | 2018-12-27 | シンダックス ファーマシューティカルズ，インコーポレイティド | 卵巣がんの処置のためのｈｄａｃ阻害剤および抗ｐｄ−ｌ１抗体の組合せ |
| US20170210803A1 (en) * | 2016-01-21 | 2017-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
-
2018
- 2018-10-18 CN CN201880071877.6A patent/CN111315783A/zh active Pending
- 2018-10-18 WO PCT/US2018/056442 patent/WO2019079549A1/en not_active Ceased
- 2018-10-18 CA CA3078430A patent/CA3078430A1/en active Pending
- 2018-10-18 KR KR1020207014146A patent/KR20200070341A/ko not_active Ceased
- 2018-10-18 US US16/756,790 patent/US20210047416A1/en not_active Abandoned
- 2018-10-18 PT PT188071450T patent/PT3697819T/pt unknown
- 2018-10-18 JP JP2020521860A patent/JP7308190B2/ja active Active
- 2018-10-18 EP EP18807145.0A patent/EP3697819B1/en active Active
- 2018-10-18 ES ES18807145T patent/ES2938652T3/es active Active
- 2018-10-18 SI SI201830820T patent/SI3697819T1/sl unknown
- 2018-10-18 PL PL18807145.0T patent/PL3697819T3/pl unknown
- 2018-10-18 AU AU2018351007A patent/AU2018351007B2/en active Active
- 2018-10-18 EP EP22207465.0A patent/EP4194470A1/en active Pending
-
2022
- 2022-11-22 JP JP2022186496A patent/JP7474827B2/ja active Active
-
2024
- 2024-01-12 JP JP2024003136A patent/JP2024024121A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500336A5 (https=) | ||
| KR102329584B1 (ko) | 종양 치료용 항-ｂ7-ｈ1 항체 | |
| JP2021500349A5 (https=) | ||
| JP2009539841A (ja) | 自己免疫疾患の治療における抗ｃｄ３抗体の投与 | |
| TW202529804A (zh) | 用於癌症治療的組合療法 | |
| US20260109766A1 (en) | Lag-3 antagonist therapy for melanoma | |
| US20210292415A1 (en) | Methods of treating a tumor | |
| WO2021250533A1 (en) | Methods of treatment using omalizumab or ligelizumab | |
| CN118176214A (zh) | 血液癌症的lag-3拮抗剂疗法 | |
| US20240425577A1 (en) | Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa | |
| KR20250099779A (ko) | 항-c5 항체/c5 irna 통합-제형 및 조합 요법 | |
| TW202228772A (zh) | 藉由併用阿替利珠單抗、托珠單抗、吉西他濱、白蛋白結合紫杉醇之4劑的胰臟癌治療劑 | |
| EP4595980A1 (en) | Method for treating membranous nephropathy with taci-fc fusion protein | |
| US20250332252A1 (en) | Antibody compositions and methods of use thereof | |
| WO2023164662A1 (en) | Treatment of squamous non small cell lung cancer | |
| WO2024099387A1 (zh) | 通过施用配体-药物偶联体治疗癌症 | |
| WO2024193675A1 (zh) | 通过施用配体-药物偶联体治疗卵巢癌 | |
| CN119630418A (zh) | 抗GARP-TGF-β1/PD-1组合疗法 | |
| CN116568307A (zh) | 用于肺癌的lag-3拮抗剂疗法 | |
| CN120456895A (zh) | 使用结合egfr的抗体与细胞毒性药物的组合的癌症治疗 | |
| CN121003695A (zh) | 抗tigit抗体和抗pd-1抗体联合治疗肿瘤 | |
| HK1224560A1 (en) | Anti-b7-h1 antibodies for treating tumors |